Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Echinobase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
Echinobase
ECB-ART-39797
Br J Cancer 2006 Jun 05;9411:1604-9. doi: 10.1038/sj.bjc.6603141.
Show Gene links Show Anatomy links

Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer.

Ciardiello F , Troiani T , Caputo F , De Laurentiis M , Tortora G , Palmieri G , De Vita F , Diadema MR , Orditura M , Colantuoni G , Gridelli C , Catalano G , De Placido S , Bianco AR .


???displayArticle.abstract???
We have evaluated the activity and safety of gefitinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in combination with docetaxel as first-line treatment of women with metastatic breast cancer (MBC). In total, 41 patients with MBC were enrolled in a first-line combination therapy study with oral gefitinib (250 mg day(-1)) and intravenous docetaxel (75 mg m(-2), the first 14 patients; or 100 mg m(-2), the following 27 patients, on day 1 of a 3-week cycle). Out of 41 patients, 38 received at least one cycle of therapy. There were no differences in activity or tolerability between the two docetaxel doses. G3/4 toxicities were neutropenia (49%), diarrhoea (10%), acne-like rash (5%), and anaemia (2%). Complete plus partial responses (CR+PR) were observed in 22 out of 41 patients with a 54% response rate (95% confidence interval (CI) 45-75%). The 22 patients that achieved a response following six cycles of docetaxel plus gefitinib continued gefitinib monotherapy (median duration, 24 weeks; range, 2-108+ weeks). Two patients with PR following combination therapy achieved a CR during gefitinib monotherapy. Complete plus partial responses correlated with oestrogen receptor (ER) status, since they occurred in 19 out of 27 (70%) patients with ER-positive tumours as compared to three out of 14 (21%) patients with ER-negative tumours (P=0.01).

???displayArticle.pubmedLink??? 16685276
???displayArticle.pmcLink??? PMC2361320
???displayArticle.link??? Br J Cancer


Genes referenced: LOC586488

References [+] :
Baselga, Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. 1996, Pubmed